XML 65 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Note 6 - Acquired Intangible Assets, Net
 12 Months Ended
Dec. 31, 2019
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]
6.
Acquired Intangible Assets, Net
 
Intangible assets consist of the following:
 
        December 31, 2019   December 31, 2018    
    Gross
Value		   Accumulated
Currency
Translation
Adjustment		   Impairment   Accumulated
Amortization		   Net Book
Value		   Accumulated
Currency
Translation
Adjustment		   Accumulated
Amortization		   Net Book
Value		   Useful
Life
Developed technology   $
17,100
     $
(2,934
 )   $
(389
 )   $
(9,657
 )   $
4,120
     $
(2,824
 )   $
(8,672
 )   $
5,604
    
15
In-process research & development    
4,406
      
(1,234
 )    
–
      
–
      
3,172
      
(1,168
 )    
–
      
3,238
    
Indefinite
Distributor relationships    
4,700
      
(415
 )    
–
      
(4,285
 )    
–
      
(415
 )    
(4,285
 )    
–
    
5
Patents    
1,000
      
(176
 )    
–
      
(531
 )    
293
      
(169
 )    
(482
 )    
349
    
16
Elevess trade name    
1,000
      
–
      
–
      
(1,000
 )    
–
      
–
      
(1,000
 )    
–
    
9
Total   $
28,206
     $
(4,759
 )   $
(389
 )   $
(15,473
 )   $
7,585
     $
(4,576
 )   $
(14,439
 )   $
9,191
    
 
 
The Company performed an annual assessment of IPR&D intangible assets as of
November 30, 2019. 
Based upon that assessment, for the fiscal year
2019
there were
no
events or changes in circumstances that would result in a change in the carrying value of IPR&D. 
 
Total amortization expense was
$1.0
million for each of the years ended
December 
31,
2019,
2018,
and
2017.
Amortization expense on intangible assets is expected to be approximately
$0.9
million in
2020,
$0.9
million annually through
2023,
and approximately
$1.0
million in aggregate thereafter.
 
The Company recorded a
$0.4
million of impairments during
2019
including a
$0.3
million impairment charge for the HYALOSPINE developed technology asset as the Company made the decision
not
to renew its CE Mark as the product was
not
aligned with the Company’s core strategic focus. The impairment charge was recorded in selling, general & administrative expenses on the Company’s consolidated statements of operations.